Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 7/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | ARHGDIA | P52565 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153691 | 0.84 | MCHR1 (0.60) | KCNH2OPRK1DRD2CYP2D6 | |
| SCHEMBL6153741 | 0.80 | DRD4 (0.61) | DRD2ROCK2ROCK1 | |
| SCHEMBL6154970 | 0.80 | MCHR1 (0.56) | KCNH2OPRK1DRD2CYP2D6ROCK2 | |
| SCHEMBL9021904 | 0.80 | DRD2 (0.62) | DRD2CYP2D6CYP2C19 | |
| SCHEMBL6154307 | 0.79 | ROCK2 (0.47) | DRD2SUV39H2ROCK2ROCK1 | |
| SCHEMBL6154310 | 0.79 | ROCK2 (0.47) | DRD2SUV39H2ROCK2ROCK1 | |
| SCHEMBL9021623 | 0.76 | DRD2 (0.68) | OPRK1DRD2CYP2D6CYP2C19 | |
| SCHEMBL6154274 | 0.75 | HTR4 (0.50) | — | |
| SCHEMBL6153423 | 0.75 | MCHR1 (0.62) | KCNH2OPRK1DRD2LTA4HCYP2D6 | |
| SCHEMBL6154287 | 0.74 | PARP15 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | KCNH2 118/4885OPRK1 947/4885OPRM1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.